(NYSE: HAE) Haemonetics's forecast annual revenue growth rate of 3.64% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.91%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Haemonetics's revenue in 2025 is $1,360,824,000.On average, 4 Wall Street analysts forecast HAE's revenue for 2026 to be $62,611,276,475, with the lowest HAE revenue forecast at $62,468,270,338, and the highest HAE revenue forecast at $62,785,314,512. On average, 4 Wall Street analysts forecast HAE's revenue for 2027 to be $67,620,238,159, with the lowest HAE revenue forecast at $67,294,066,956, and the highest HAE revenue forecast at $68,099,167,009.
In 2028, HAE is forecast to generate $72,809,482,689 in revenue, with the lowest revenue forecast at $72,447,475,887 and the highest revenue forecast at $73,471,624,642.